The problem with the broad-based selling, however, is not all stocks in the sector are overvalued—including many of its leaders. Amgen is now trading at 14 times its 2015 estimated earnings, while Biogen is trading at 17 times earnings, and Gilead Sciences at a mere 8 times 2015 earnings. All...